Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER.
AMINOSYN II 3.5% IN PLASTIC CONTAINER vs AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis and maintenance of nitrogen balance. The amino acids serve as substrates for protein synthesis, and their metabolism yields nitrogen for ureagenesis and carbon skeletons for gluconeogenesis or oxidation.
Aminosyn II 4.25% in Dextrose 10% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories to prevent catabolism. The mechanism involves intravenous administration bypassing gastrointestinal tract, directly providing essential and non-essential amino acids for anabolism and energy in the form of glucose.
Intravenous infusion of 3.5% amino acid solution at a rate of 1-2 mL/kg/hour (equivalent to 0.035-0.07 g amino acids/kg/hour) for protein supplementation, not to exceed 0.2 g nitrogen/kg/day. Dosage individualized based on metabolic needs and clinical response.
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day by central line, providing 4.25% amino acids and 10% dextrose. Infusion rate typically 1-2 mL/min initially, adjusted to provide 1-1.5 g/kg/day of amino acids and 3-4 g/kg/day of dextrose.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is not typically defined as a single value because they are rapidly cleared from plasma for protein synthesis and metabolic processes. For labeled amino acids, the plasma clearance half-life ranges from 10-30 minutes. Clinically, the half-life is short; continuous infusion is required to maintain plasma amino acid levels. In patients with hepatic or renal dysfunction, half-life may be prolonged.
Not applicable as a fixed agent; amino acids have distribution half-life of 15-30 min; dextrose has elimination half-life of 1.5-2.5 hours depending on metabolic state.
Aminosyn II 3.5% is a crystalline amino acid solution. The amino acids are metabolized and utilized for protein synthesis. Excess nitrogen is converted to urea in the liver and excreted renally as urea. Approximately 80-90% of infused amino acids are incorporated into proteins or metabolized; the remainder is excreted in urine as urea and other nitrogenous wastes. Fecal excretion is negligible (less than 2%) as amino acids are not significantly eliminated in bile. In patients with renal impairment, urea excretion is decreased, leading to azotemia.
Amino acids are metabolized to urea and other nitrogenous wastes; renal excretion of metabolites accounts for >90% of nitrogen elimination, with <5% excreted unchanged in urine. Dextrose is fully metabolized to CO2 and water.
Category C
Category C
Amino Acid Solution
Amino Acid Solution